Invega Trinza 175 mg

Invega Trinza 175 mg is an extended-release suspension of paliperidone palmitate, used for long-term management of schizophrenia. This intramuscular injection is designed for maintenance treatment, administered by healthcare professionals.

Invega Trinza 175 mg is primarily used for the maintenance treatment of schizophrenia in adults who have been stabilized on paliperidone palmitate. This medication is part of a treatment plan to manage symptoms and prevent relapse. It is not intended for initial treatment but rather for long-term management after stabilization.

Common effects of Invega Trinza 175 mg may include injection site reactions, weight gain, and changes in metabolism. Some individuals may experience drowsiness or dizziness. It is important to discuss any persistent or severe side effects with a healthcare provider.

Invega Trinza 175 mg should be administered by a healthcare professional. It is important to monitor for signs of metabolic changes, such as weight gain or high blood sugar. Regular follow-ups are recommended to ensure the medication's effectiveness and safety.

Invega Trinza 175 mg may interact with other medications, including those that affect the central nervous system. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol should be avoided as it may exacerbate side effects.